Tech Company Financing Transactions
Bridge Medicines Funding Round
Bridge Medicines, operating out of New York, secured $10 million in funding from private investors.
Transaction Overview
Company Name
Announced On
11/16/2020
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance its current pipeline of products as well as expand with additional in-licensed technologies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
780 3rd Ave.
New York, NY 10017
USA
New York, NY 10017
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Bridge Medicines is a drug discovery company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Carl Goldfischer
Chief Executive Officer
William Polvino
Chief Scientific Officer
Louis Renzetti
Browse more venture capital transactions:
Prev: 11/13/2020: Dimension venture capital transaction
Next: 11/16/2020: Curbio venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs